Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial

The Lancet 2026 Open access

Read full text
Authors: Meletios Α. Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, Monique Hartley-Brown, Cesar Gomez, Donna Reece, Gábor Mikala, Omar Alkharabsheh, Christopher Parrish, Edvan de Queiroz Crusoé, Kenny Galvez, Henry Idrobo
+35 more Darrell White, Ridhi Gupta, Cindy Lee, Chia-Jen Liu, Hang Quach, Yafei Wang, Claudio Cerchione, Cecily Forsyth, Vania Hungria, Pritam Kalaskar, Vasko Graklanov, Phoebe Joy Ho, Maika Klaiber-Hakimi, Yok Lam Kwong, Martha Louzada Júnior, Amitabha Mazumder, Oliver Miles, Chandramouli Nagarajan, Sripada V S S Prasad, Marc S. Raab, Gergely Varga, Eyck von der Heyde, Zhongjun Xia, Paola Andrea Ochoa, Albert Oriol, Junichiro Yuda, Junya Kuroda, Jing Gong, Zehua Zhou, Paulo Maciag, Brian Yu, Alberto Rocci, Phillip Koo, J. Katz, Paul G. Richardson
DOI: 10.1016/s0140-6736(26)01088-3
Cited by: 4
References: 32

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment Cancer Treatment and Pharmacology

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
408
Issue
10551
Pages
219–233
Publication date
14 June 2026
Language
EN